Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | EQ |
---|---|---|
09:32 ET | 1455 | 0.6789 |
09:38 ET | 699 | 0.6682 |
09:45 ET | 460 | 0.6684 |
09:50 ET | 100 | 0.6749 |
10:03 ET | 1047 | 0.6749 |
10:08 ET | 100 | 0.6749 |
10:21 ET | 2755 | 0.66 |
10:44 ET | 300 | 0.673 |
10:46 ET | 800 | 0.6709 |
11:02 ET | 2973 | 0.66 |
11:11 ET | 104 | 0.6709 |
11:15 ET | 300 | 0.66 |
11:18 ET | 101 | 0.66 |
11:26 ET | 150 | 0.664451 |
11:27 ET | 5741 | 0.656351 |
11:40 ET | 1132 | 0.6558 |
11:45 ET | 1000 | 0.6669 |
12:09 ET | 456 | 0.650201 |
12:38 ET | 3522 | 0.652 |
12:39 ET | 105 | 0.661267 |
01:14 ET | 2000 | 0.665 |
01:44 ET | 200 | 0.665 |
01:50 ET | 500 | 0.665 |
02:13 ET | 1462 | 0.6629 |
02:15 ET | 200 | 0.663 |
02:27 ET | 122 | 0.664 |
03:45 ET | 4649 | 0.669 |
03:52 ET | 5436 | 0.7 |
03:59 ET | 34890 | 0.6932 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Equillium Inc | 24.4M | -2.0x | --- |
Microalliance Group Inc | 36.6M | 4.4x | --- |
Biofrontera Inc | 4.6M | -0.1x | --- |
Health-Chem Corp | 1.2K | 0.0x | --- |
Bon Natural Life Ltd | 9.6M | 0.5x | +78.05% |
Qilian International Holding Group Ltd | 23.8M | -3.1x | --- |
Equillium, Inc. is a clinical-stage biotechnology company. It is engaged in developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The Company’s pipeline consists of immunomodulatory assets and a product platform targeting immuno-inflammatory pathways. The Company’s EQ101 is a selective tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15. The EQ302 is an orally delivered, selective bi-specific cytokine inhibitor targeting IL-15 and IL-21. It is in pre-clinical development. Its multi-cytokine platform generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level targeting pathogenic cytokine redundancies and synergies while preserving non-pathogenic signaling. The Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $24.4M |
---|---|
Revenue (TTM) | $37.9M |
Shares Outstanding | 35.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.80 |
EPS | $-0.35 |
Book Value | $0.64 |
P/E Ratio | -2.0x |
Price/Sales (TTM) | 0.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -34.85% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.